Moshe C. Ornstein MD MA of the Cleveland Clinic Taussig Cancer Institute presents “Clinical Effect of TKI Dose-Escalation after Disease Progression in Patients with Metastatic Renal Cell Carcinoma” at the 14th International Kidney Cancer Symposium.
Advertisement
Clinical Effect of TKI Dose-Escalation after Disease Progression in Patients with Metastatic Renal Cell Carcinoma
By Editor